← Leaderboards
Dennis Roop
Oregon Health & Science University
$22,231,168
Attributed
$26,136,322
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,932,547 · 17
By mechanism
R01$16,902,206 · 7
P01$6,796,225 · 2
U01$5,261,563 · 2
T32$2,997,795 · 1
UG3$538,200 · 1
N01$257,719 · 1
Top collaborators
- David A. Norris7 shared
- Yosef Refaeli5 shared
- Jakub Tolar5 shared
- Sancy Ann Leachman4 shared
- Maryam Mandana Asgari3 shared
- Ganna Bilousova2 shared
- Anna Lee Bruckner1 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Sancy Ann Leachman$2,764,455
Others in their field
Top investigators on “Skin”
- David Heimbrook · Leidos Biomedical Research, Inc.$121,104,269
- Donald Ym Leung · University Of Colorado Denver$58,473,424
- Thomas S. Kupper · Dana-Farber Cancer Institute$53,329,207
- Elaine Fuchs · University Of Chicago$41,573,105
- Timothy Burgess · National Institute Of Allergy And Infectious Diseases$35,600,000
- David Leung · National Jewish Health$31,859,607
Research focus
SkinKeratinocyteSkin DisorderMutationPhenotypeMouse ModelGenesProteinsGeneticLaboratory MouseEpidermisGenerationsCellsBaseImmuneStem CellsMolecularBiopsyAreaKeratinGene ExpressionClinicGenetically Modified AnimalsExhibits
Grant awards (81)
Defining the role of innate immune cells in the early stages of immune surveillance of skin cancer by using a novel model that allows in vivo imaging of the immunoediting process.$457,791
R01 · FY2025 · AR · contact PI
Training in Translational Research of Skin Diseases$311,926
T32 · FY2025 · AR · contact PI
Montagna Symposium on the Biology of Skin$47,560
R13 · FY2025 · AR
Defining the role of innate immune cells in the early stages of immune surveillance of skin cancer by using a novel model that allows in vivo imaging of the immunoediting process.$493,397
R01 · FY2024 · AR · contact PI
Training in Translational Research of Skin Diseases$229,498
T32 · FY2024 · AR · contact PI
Montagna Symposium on the Biology of Skin$30,000
R13 · FY2024 · AR
Montagna Symposium on the Biology of Skin$17,560
R13 · FY2024 · AR
Study of the Safety, Tolerability, and Efficacy of an iPS Cell-based Therapy for Recessive Dystrophic Epidermolysis Bullosa Delivered with a Spray on Skin Device$538,200
UG3 · FY2023 · AR · contact PI
Defining the role of innate immune cells in the early stages of immune surveillance of skin cancer by using a novel model that allows in vivo imaging of the immunoediting process.$508,656
R01 · FY2023 · AR · contact PI
Training in Translational Research of Skin Diseases$265,098
T32 · FY2023 · AR · contact PI
Montagna Symposium on the Biology of Skin$30,000
R13 · FY2023 · AR
Defining the role of innate immune cells in the early stages of immune surveillance of skin cancer by using a novel model that allows in vivo imaging of the immunoediting process.$508,656
R01 · FY2022 · AR · contact PI
Training in Translational Research of Skin Diseases$313,308
T32 · FY2022 · AR · contact PI
Training in Translational Research of Skin Diseases$375,652
T32 · FY2021 · AR · contact PI
Exploring Alternative iPS Cell Therapies for Recessive Dystrophic Epidermolysis Bullosa$419,231
U01 · FY2020 · AR · contact PI
Exploring Alternative iPS Cell Therapies for Recessive Dystrophic Epidermolysis Bullosa$388,750
U01 · FY2019 · AR · contact PI
Training in Immunodermatology$344,239
T32 · FY2019 · AR · contact PI
Training in Immunodermatology$305,827
T32 · FY2018 · AR · contact PI
Testing the Therapeutic Potential of iPS Cells for Inherited Skin Diseases$428,909
R01 · FY2017 · AR · contact PI
Training in Immunodermatology$271,164
T32 · FY2017 · AR · contact PI
Testing the Therapeutic Potential of iPS Cells for Inherited Skin Diseases$345,938
R01 · FY2016 · AR · contact PI
Training in Immunodermatology$278,600
T32 · FY2016 · AR · contact PI
Targeting Oncogene Expression to Skin in Transgenic Mice$475,014
R01 · FY2015 · CA · contact PI
Testing the Therapeutic Potential of iPS Cells for Inherited Skin Diseases$345,938
R01 · FY2015 · AR · contact PI
The consequences of loricrin deficiency on epidermal barrier function$329,940
R01 · FY2015 · AR · contact PI
Training in Immunodermatology$302,483
T32 · FY2015 · AR · contact PI
2015 Barrier Function of Mammalian Skin Gordon Research Conference$15,000
R13 · FY2015 · AR · contact PI
Targeting Oncogene Expression to Skin in Transgenic Mice$462,072
R01 · FY2014 · CA · contact PI
Testing the Therapeutic Potential of iPS Cells for Inherited Skin Diseases$338,558
R01 · FY2014 · AR · contact PI
The consequences of loricrin deficiency on epidermal barrier function$323,341
R01 · FY2014 · AR · contact PI
Targeting Oncogene Expression to Skin in Transgenic Mice$449,076
R01 · FY2013 · CA · contact PI
Testing the Therapeutic Potential of iPS Cells for Inherited Skin Diseases$327,661
R01 · FY2013 · AR · contact PI
The consequences of loricrin deficiency on epidermal barrier function$313,443
R01 · FY2013 · AR · contact PI
Targeting Oncogene Expression to Skin in Transgenic Mice$479,145
R01 · FY2012 · CA · contact PI
Testing the Therapeutic Potential of iPS Cells for Inherited Skin Diseases$356,513
R01 · FY2012 · AR · contact PI
The consequences of loricrin deficiency on epidermal barrier function$329,940
R01 · FY2012 · AR · contact PI
Targeting Oncogene Expression to Skin in Transgenic Mice$480,576
R01 · FY2011 · CA · contact PI
The consequences of loricrin deficiency on epidermal barrier function$329,940
R01 · FY2011 · AR · contact PI
Regulation and Function of Keratins in the Epidermis$32,278
R01 · FY2010 · AR · contact PI
INDUCIBLE MOUSE MODELS FOR SKIN AND HEAD AND NECK CANCER$214,000
U01 · FY2009 · CA · contact PI
The Denver Network of the NHLBI Progenitor Cell Biology Consortium$38,719
R03 · FY2009 · HL · contact PI
Regulation and Function of Keratins in the Epidermis$35,564
R01 · FY2009 · AR · contact PI
INDUCIBLE MOUSE MODELS FOR SKIN AND HEAD AND NECK CANCER$820,068
U01 · FY2008 · CA · contact PI
Targeting Oncogene Expression to Skin in Transgenic Mice$487,219
R01 · FY2008 · CA · contact PI
Regulation and Function of Keratins in the Epidermis$309,624
R01 · FY2008 · AR · contact PI
INDUCIBLE MOUSE MODELS FOR SKIN AND HEAD AND NECK CANCER$946,614
U01 · FY2007 · CA · contact PI
Targeting Oncogene Expression to Skin in Transgenic Mice$490,305
R01 · FY2007 · CA · contact PI
TESTING GENE THERAPY FOR EPIDERMOLYSIS BULLOSA SIMPLEX$324,210
R01 · FY2007 · AR · contact PI
Regulation and Function of Keratins in the Epidermis$283,664
R01 · FY2007 · AR · contact PI
Regulation and Function of Keratins in the Epidermis$32,278
R01 · FY2007 · AR · contact PI
INDUCIBLE MOUSE MODELS FOR SKIN AND HEAD AND NECK CANCER$820,301
U01 · FY2006 · CA · contact PI
Targeting Oncogene Expression to Skin in Transgenic Mice$490,241
R01 · FY2006 · CA · contact PI
TESTING GENE THERAPY FOR EPIDERMOLYSIS BULLOSA SIMPLEX$376,128
R01 · FY2006 · AR · contact PI
Regulation and Function of Keratins in the Epidermis$334,342
R01 · FY2006 · AR · contact PI
Molecular Mechanisms of Skin and Appendage Development$1,439,200
P01 · FY2005 · AR
INDUCIBLE MOUSE MODELS FOR SKIN AND HEAD AND NECK CANCER$802,599
U01 · FY2005 · CA
Targeting Oncogene Expression to Skin in Transgenic Mice$487,415
R01 · FY2005 · CA
TESTING GENE THERAPY FOR EPIDERMOLYSIS BULLOSA SIMPLEX$364,963
R01 · FY2005 · AR
Regulation and Function of Keratins in the Epidermis$342,388
R01 · FY2005 · AR
TESTING GENE THERAPY FOR EPIDERMOLYSIS BULLOSA SIMPLEX$48,434
R01 · FY2005 · AR
Molecular Mechanisms of Skin and Appendage Development$1,397,280
P01 · FY2004 · AR
INDUCIBLE MOUSE MODELS FOR SKIN AND HEAD AND NECK CANCER$850,000
U01 · FY2004 · CA
Targeting Oncogene Expression to Skin in Transgenic Mice$473,219
R01 · FY2004 · CA
TESTING GENE THERAPY FOR EPIDERMOLYSIS BULLOSA SIMPLEX$364,963
R01 · FY2004 · AR
Regulation and Function of Keratins in the Epidermis$342,388
R01 · FY2004 · AR
Molecular Mechanisms of Skin and Appendage Development$1,356,584
P01 · FY2003 · AR
TARGETING ONCOGENE EXPRESSION TO SKIN IN TRANSGENIC MICE$470,125
R01 · FY2003 · CA
TESTING GENE THERAPY FOR EPIDERMOLYSIS BULLOSA SIMPLEX$364,963
R01 · FY2003 · AR
REGULATION AND FUNCTION OF KERATINS IN THE EPIDERMIS$300,297
R01 · FY2003 · HD
Molecular Mechanisms of Skin and Appendage Development$1,317,074
P01 · FY2002 · AR
TARGETING ONCOGENE EXPRESSION TO SKIN IN TRANSGENIC MICE$457,612
R01 · FY2002 · CA
REGULATION AND FUNCTION OF KERATINS IN THE EPIDERMIS$292,503
R01 · FY2002 · HD
Development of epidermal barrier function$0
P01 · FY2002 · AR
Molecular Mechanisms of Skin and Appendage Development$1,286,087
P01 · FY2001 · AR
TARGETING ONCOGENE EXPRESSION TO SKIN IN TRANSGENIC MICE$370,462
R01 · FY2001 · CA
REGULATION AND FUNCTION OF KERATINS IN THE EPIDERMIS$284,932
R01 · FY2001 · HD
TARGETING ONCOGENE EXPRESSION TO SKIN IN TRANSGENIC MICE$18,750
R01 · FY2001 · CA
Development of epidermal barrier function$0
P01 · FY2001 · AR
TARGETING ONCOGENE EXPRESSION TO SKIN IN TRANSGENIC MICE$360,850
R01 · FY2000 · CA
REGULATION AND FUNCTION OF KERATINS IN THE EPIDERMIS$277,585
R01 · FY2000 · HD
DEVELOPMENT OF EXPERIMENTAL MODELS OF EB SIMPLEX$257,719
N01 · FY2000 · AR